SyndicateRoom portfolio companies defy tough markets to make significant progress
The Fund co-invests with UK-leading angel backers to build for investors large, sector-agnostic portfolios involving some of the UK’s most exciting startups.
Investee businesses continue to make crucial breakthroughs and hit milestones that underline their growth potential while highlighting the unique deal-sourcing approach of the Cambridge-based fund.
"It's been a tough environment for all startups so we are delighted to see so many companies making exceptional progress,” said Tom Britton, Founding Partner at SyndicateRoom.
Chief among them is Cambridge-anchored Porotech which, as Business Weekly recently reported, has joined forces with multinational giant Foxconn in Taiwan to bring MicroLED technology to the augmented reality market.
Porotech’s bleeding edge proposition represents a revolution in the display and semiconductor industries. Its latest partnership will see its innovative gallium nitride (GaN) technology integrated with the latest global AR and micro-display technology as Foxconn enters the Augmented Reality glasses segment.
Foxconn has revealed its plans to establish a MicroLED wafer processing production line in Taichung, Taiwan, and expects mass production to begin in the fourth quarter of 2025.
Porotech CEO Dr Tongtong Zhu commented: “Our collaboration with Foxconn, PSMC, and GIS in 2024 is a significant technological milestone and a testament to our commitment to accelerating the commercialisation of MicroLED technology.
“We look forward to these technological achievements bringing new value to AR glasses and global technology as a whole.”
Monument Therapeutics, a spin-out from Cambridge Cognition, was significantly awarded a Chinese patent to support its MT1988 programme targeting cognitive impairment associated with schizophrenia.
Monument is a UK clinical-stage biotech that uses digital biomarkers to develop targeted treatments for areas of high unmet need in psychiatry and neurology.
The current pipeline focuses on two core treatments initially targeting cognitive impairment associated with schizophrenia and neuroinflammation.
“Securing patent protection in China, one the world’s largest healthcare markets, is a substantial achievement for Monument Therapeutics,” said Jenny Barnett, the company’s CEO.
London-based pension-finding platform Raindrop is bringing sunshine through the storm for customers. It has recovered for UK savers more than £251 million worth of ‘lost’ pension pots in the last 12 months and reunited them with their money.
That recovery haul represented a 61 per cent increase over the prior 12 months. Staggeringly, £26.6 billion worth of pensions go unclaimed annually in the UK. Raindrop says that the 18,000 lost pension pots located in 2024 carried an average value of £14,000.
Another Syndicate Room-backed business doing exceptionally well is Oxford Drug Design – an AI-driven drug discovery company which has achieved further success through a key colorectal cancer study.
Oxford Drug Design’s latest venture – a colorectal cancer model study on mice – indicated a clear efficacy and dose response that led to a 60 per cent life extension.
The company attributes these advances to its unique discovery platform, which deploys an integrated Generative AI capability alongside the team’s much vaunted tRNA synthetase expertise.
CEO Dr Alan Roth says: “This new milestone for Oxford Drug Design is a testament not only to the accuracy and reliability of our computational platform, SynthAI, but also to the expertise of our team.”
Tom Britton expects more exciting successes throughout 2025 and readers are invited to follow the news and access more details about its funds and investee companies through its portfolio page.